HomeAI · summaries
Storia in 2 fonti
Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC
Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Pathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERα PROTAC for ER+ Breast Cancer into the Clinic
Pathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERα PROTAC for ER+ Breast Cancer into the Clinic
- ·
endpoints.news
Exclusive: Pathos AI signs two deals, plans to raise Series E at $3B valuation
Pathos AI is raising up to $300M at a ~$3B valuation and inks deals for Alphamab's TROP2/HER3 ADC ($125M upfront) and AstraZeneca's oral ER degrader.
